NCT03109756View on ClinicalTrials.gov

Single Dose Pharmacokinetic (PK) Study

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

April 3, 2017

Primary Completion Date

November 28, 2017

Study Completion Date

November 28, 2017

Conditions

Angelman SyndromeFragile X Syndrome

Interventions

DRUG

OV101

Single-dose 5 mg OV101

Trial Locations (2)

37212

Ovid Therapeutics Investigative Site, Nashville

60612

Ovid Therapeutics Investigative Site, Chicago

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Healx AI

INDUSTRY

NCT03109756 - Single Dose Pharmacokinetic (PK) Study | Biotech Hunter | Biotech Hunter